Sodium Chloride


B. Braun Medical Inc.
Human Prescription Drug
NDC 0264-9375
Sodium Chloride is a human prescription drug labeled by 'B. Braun Medical Inc.'. National Drug Code (NDC) number for Sodium Chloride is 0264-9375. This drug is available in dosage form of Injection. The names of the active, medicinal ingredients in Sodium Chloride drug includes Sodium Chloride - 9 mg/mL . The currest status of Sodium Chloride drug is Active.

Drug Information:

Drug NDC: 0264-9375
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Sodium Chloride
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Sodium Chloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: B. Braun Medical Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:SODIUM CHLORIDE - 9 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 09 Aug, 2016
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 17 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA019635
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:B. Braun Medical Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1807637
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:451W47IQ8X
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Increased Large Intestinal Motility [PE]
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Osmotic Activity [MoA]
Osmotic Laxative [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0264-9375-8810 mL in 1 AMPULE (0264-9375-88)09 Aug, 2016N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Sodium chloride sodium chloride sodium chloride sodium cation chloride ion

Indications and Usage:

Indications and usage 0.9% sodium chloride injection usp is indicated as pharmaceutic aid and diluent for the infusion of compatible drug additives. refer to prescribing information accompanying additive drugs.

Warnings:

Warnings the administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. the risk of dilutional states is inversely proportional to the electrolyte concentration. the risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration. solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there is sodium retention with edema. in patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. infusion of isotonic (0.9%) sodium chloride during or immediately after surgery may result in excessive sodium retention. use the patient’s circulatory system status as a guide.

General Precautions:

General clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. significant deviations from normal concentrations may require tailoring of the electrolyte pattern, in these or alternative solutions. since sodium chloride injection does not contain antimicrobial agents and is intended for single use, any unused amount must be discarded immediately following withdrawal of any portion of the contents of the ampoule. do not open ampoule until it is to be used. this solution should be used with care in patients with hypervolemia, renal insufficiency, urinary tract obstruction, or impending or frank cardiac decompensation. consult the manufactures instructions for choice of vehicle, appropriate dilution or volume for dissolving the drug to be injected, including the route and rate of inje
ction. extraordinary electrolyte losses such as may occur during protracted nasogastric suction, vomiting, diarrhea or gastrointestinal fistula drainage may necessitate additional electrolyte supplementation. additional essential electrolytes, minerals and vitamins should be supplied as needed. sodium-containing solutions should be administered with caution to patients receiving corticosteroids or corticotropin, or to other salt-retaining patients. care should be exercised in administering solutions containing sodium to patients with renal or cardiovascular insufficiency, with or without congestive heart failure, particularly if they are postoperative or elderly. infusion of more than one liter of isotonic (0.9%) sodium chloride per day may supply more sodium and chloride than normally found in serum, and can exceed normal tolerance, resulting in hypernatremia; this may also cause a loss of bicarbonate ions, resulting in an acidifying effect. to minimize the risk of possible incompatibilities arising from mixing this solution with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration and periodically during administration. if administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. this solution is intended for intravenous administration using sterile equipment. it is recommended that intravenous administration apparatus be replaced at least once every 24 hours. use only if solution is clear and container and glass ampoule is intact.

Dosage and Administration:

Dosage and administration this solution is for intravenous use only. dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy. in the average adult, daily requirements of sodium and chloride are met by the infusion of one liter of 0.9% sodium chloride (154 meq each of sodium and chloride). there is no specific pediatric dose. the dose is dependent on weight, clinical condition and laboratory results. follow recommendations of appropriate pediatric reference text. (see precautions, pediatric use . ) fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient. 0.9% sodium chloride injection usp may also be administered intravascularly as a primin
g fluid in hemodialysis procedures. when sodium chloride injections usp are used as diluents for infusion of compatible drug additives, refer to dosage and administration information accompanying additive drugs. some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Contraindications:

Contraindications this solution is contraindicated where the administration of sodium or chloride could be clinically detrimental.

Adverse Reactions:

Adverse reactions reactions which may occur because of the solution, added drugs or the technique of reconstitution or administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. carefully review the prescribing information for the diluted drug. the physician should also be alert to the possibility of adverse reactions to drug additives. prescribing information for drug additives to be administered in this manner should be consulted. symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential. hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume. if infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying
effect. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

Use in Pregnancy:

Pregnancy teratogenic effects pregnancy category c. animal reproduction studies have not been conducted with 0.9% sodium chloride injection usp. it is also not known whether 0.9% sodium chloride injection usp can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. 0.9% sodium chloride injection usp should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Pediatric use safety and effectiveness of sodium chloride injections in pediatric patients have not been established by adequate and well controlled trials, however, the use of electrolyte solutions in the pediatric population is referenced in the medical literature. the warnings, precautions and adverse reactions identified in the label copy should be observed in the pediatric population.

Geriatric Use:

Geriatric use an evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Overdosage:

Overdosage in the event of a fluid or solute overload during parenteral therapy, reevaluate the patient’s condition and institute appropriate corrective treatment.

Description:

Description each 1 ml of 0.9% sodium chloride injection usp contains: sodium chloride usp 9 mg water for injection usp qs ph: 5.6 (4.5-7.0) calculated osmolarity: 0.308 mosmol/ml ph adjusted with hydrochloric acid nf concentration of electrolytes (meq/liter): sodium 154 chloride 154 0.9% sodium chloride injection usp is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents. the formula of the active ingredient is: ingredient molecular formula molecular weight sodium chloride usp naci 58.44 not made with natural rubber latex, pvc or dehp.

Clinical Pharmacology:

Clinical pharmacology 0.9% sodium chloride injection usp provides electrolytes and is a source of water for hydration. it is capable of inducing diuresis depending on the clinical condition of the patient. sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid. chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility studies with 0.9% sodium chloride injection usp have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

How Supplied:

How supplied 0.9% sodium chloride injection usp is supplied sterile and nonpyrogenic in glass ampoule container. ndc size 0264-9375-88 10 ml exposure of pharmaceutical products to heat should be minimized. avoid excessive heat. protect from freezing. it is recommended that the product be stored at room temperature (25°c); however, brief exposure up to 40°c does not adversely affect the product. revised: may 2018 directions for use of ampoule to open ampoules, using gauze, place thumb and forefinger on color line, break at constriction. note: before use, perform the following checks: inspect each container. read the label. ensure solution is the one ordered and is within the expiration date. invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter. any container which is suspect should not be used. use only if solution is clear and container and seals are intact.

Package Label Principal Display Panel:

Principal display panel ndc 0264-9375-88 0.9% sodium chloride injection usp 10 ml single-dose ampoule. discard unused portion. calc. osmolarity: 0.308 mosmol/ml for dilution of medication. for intravenous use. use only if solution is clear. preservative-free protect from freezing. store at room temperature (25°c). rx only manufactured for: b. braun medical inc. bethlehem, pa 18018-3524 usa produced in germany, api from denmark. ld-521-a-4 lot exp 10 ml ampoule bottle label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.